Pharsight

Natazia patents expiration

NATAZIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071577 BAYER HLTHCARE Multi-phase contraceptive preparation based on a natural estrogen
May, 2026

(2 years from now)

US8153616 BAYER HLTHCARE Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Jan, 2028

(4 years from now)

Natazia is owned by Bayer Hlthcare.

Natazia contains Dienogest; Estradiol Valerate.

Natazia has a total of 2 drug patents out of which 0 drug patents have expired.

Natazia was authorised for market use on 06 May, 2010.

Natazia is available in tablet;oral dosage forms.

Natazia can be used as treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception, prevention of pregnancy.

The generics of Natazia are possible to be released after 30 January, 2028.

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Market Authorisation Date: 06 May, 2010

Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of NATAZIA before it's drug patent expiration?
More Information on Dosage

NATAZIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic